Antiangiogenic therapy for primary and metastatic brain tumors.
We first provide the theoretic foundation of antiangiogenic therapy by describing the biology of angiogenesis as it applies to brain tumors. We then outline experimental antiangiogenic therapies that are being applied preclinically to brain tumors, as well as published clinical trial data and ongoing clinical trials in patients. Primary and metastatic brain tumors are covered, although there is far less exploration in the literature of brain metastases.
Purow
Benjamin
B
Neuro-Oncology Branch, National Cancer Institute, National Institutes of Neurological Disorder and Stroke, National Institutes of Health, Room 235, The Bloch Building/Bldg. #82, 9030 Old Georgetown Road, Bethesda, MD 20892, USA.
Fine
Howard A
HA
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D001921:Brain / Q000098:blood supply; D001932:Brain Neoplasms / Q000098:blood supply* / Q000188:drug therapy* / Q000473:pathology; D002560:Cerebrovascular Circulation; D006801:Humans; D009362:Neoplasm Metastasis; D009389:Neovascularization, Pathologic / Q000517:prevention & control; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors / Q000502:physiology
D020533:Angiogenesis Inhibitors; D042461:Vascular Endothelial Growth Factor A